Jones Trading Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $42

Benzinga · 10/18 13:01
Jones Trading analyst Justin Walsh initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $42.